Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Wullt M;Wullt M; Hagslätt ML; Odenholt I
  • Source:
    Scandinavian journal of infectious diseases [Scand J Infect Dis] 2003; Vol. 35 (6-7), pp. 365-7.
  • Publication Type:
    Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Informa Healthcare Country of Publication: England NLM ID: 0215333 Publication Model: Print Cited Medium: Print ISSN: 0036-5548 (Print) Linking ISSN: 00365548 NLM ISO Abbreviation: Scand J Infect Dis Subsets: MEDLINE
    • Publication Information:
      Publication: 2007-2014 : London : Informa Healthcare
      Original Publication: Stockholm, Society for the Publication of Acta medica Scandinavica.
    • Subject Terms:
      Clostridioides difficile/*physiology ; Enterocolitis, Pseudomembranous/*therapy ; Lactobacillus/*physiology ; Probiotics/*therapeutic use; Aged ; Double-Blind Method ; Female ; Humans ; Male ; Metronidazole/therapeutic use ; Middle Aged ; Recurrence
    • Abstract:
      A double-blind, placebo-controlled trial was performed to analyse the ability of Lactobacillus plantarum 299v to prevent further recurrent episodes of Clostridium difficile-associated diarrhoea (RCDAD). Recurrence of clinical symptoms (main outcome) was seen in 4 of 11 patients who received metronidazole in combination with L. plantarum 299v and in 6 of 9 treated with metronidazole in combination with placebo. The lactobacilli treatment had no side-effects. Although the small sample size does not allow any conclusion to be drawn concerning the efficacy of L. plantarum in patients with RCDAD, these results may contribute to the ongoing discussion about the benefits of probiotics in patients with RCDAD and encourage the performance of larger multicentre studies.
    • Accession Number:
      140QMO216E (Metronidazole)
    • Publication Date:
      Date Created: 20030905 Date Completed: 20030926 Latest Revision: 20201208
    • Publication Date:
      20221213
    • Accession Number:
      10.1080/00365540310010985
    • Accession Number:
      12953945